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Introduction
Apolipoprotein E (APOE) is a protein that plays an important 
role in lipid metabolism (including cholesterols) and has been 
implicated in synaptogenesis, repair of injured nerve tissue and 
the modulation of beta-amyloid plaques and neurofibrillary tan-
gles that characterise Alzheimer’s disease (AD) (for review, see 
Belloy et al., 2019; Rocchi et al., 2003). The gene coding for 
APOE is located on chromosome 19 and is polymorphic in the 
general population. The three most common alleles are ε2, ε3 and 
ε4, with approximate allele frequencies of 6%, 78% and 15% in 
healthy Caucasian Europeans (Eisenberg et al., 2010). Possession 
of the ε4 allele has been associated with poorer cognitive abilities 
and more rapid longitudinal decline in healthy older people, par-
ticularly in episodic memory (e.g. Jack et al., 2015; Jochemsen 
et al., 2012; Jorm et al., 2007; Lyall et al., 2016; Marioni et al., 
2016; Mondadori et al., 2007; Schiepers et al., 2012; Schultz 
et al., 2008; Shin et al., 2014; see Wisdom et al., 2011 for a meta-
analysis). It has also been associated with a three-to-fourfold 
increase in the risk of late onset AD in a gene dose-dependent 
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Polymorphisms in the apolipoprotein E (APOE) gene have been associated with individual differences in cognition, brain structure and brain function. For 
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manner (Farrer et al., 1997) and with an earlier age at onset by 
nearly 6 years on average for ε4 carriers (Blacker et al., 1997). 
Indeed, some have argued that APOE has no influence on cogni-
tion in mid- or late-life beyond increasing risk for AD, such that 
effects found on cognition reflect the decades of a pre-sympto-
matic period of AD pathology (e.g. Vemuri et al., 2010; see also 
O’Donoghue et al., 2018).
There have also been claims that the ε4 allele confers cogni-
tive benefits earlier in life, that is, individuals aged 5–35 years 
(e.g. Puttonen et al., 2003; Rusted et al., 2013; Yu et al., 2000, 
though, see Ihle et al., 2012 for a meta-analysis of studies that 
found no consistent effect of ε4 status on cognitive tests in this 
age-group). These claims led to the ‘antagonistic pleiotropy’ 
hypothesis of Han and Bondi (2008), whereby the APOE ε4 
allele is hypothesised to be advantageous in early life but disad-
vantageous in later life (and potentially neutral in middle-age, 
consistent with the lack of association with cognition in a meta-
analysis of middle-aged people by Lancaster et al., 2017). The 
antagonistic pleiotropy hypothesis is illustrated in Figure 1 (cf. 
red versus blue lines).
Cognitive benefits in early life (while still fertile), or impair-
ments that only arise later in life, might explain in evolutionary 
terms why the ε4 allele persists in the population at a relatively 
high frequency (Fullerton et al., 2000). However, most studies of 
ε4 have examined young, middle-aged or older samples sepa-
rately. Moreover, studies of older participants are often biased by 
the over representation of super-healthy individuals who are 
motivated to respond to adverts or join volunteer panels, as 
opposed to population-based recruitments.
To examine the effect of APOE across the adult lifespan, we 
used the ‘imaging’ sample of Cambridge Centre for Ageing and 
Neuroscience (CamCAN; www.cam-can.org) to test for a con-
tinuous interaction between age and APOE status on a variety of 
cognitive and brain measures. CamCAN is a population-derived, 
lifespan cohort of healthy adults uniformly distributed from 18 to 
88 years, which allows us to overcome many of the limitations of 
former studies of the effects of ε4 at different ages.
Another strand of the literature has examined the possible 
protective effects of the ε2 allele, which has been reported to 
reduce risk of AD (Farrer et al., 1997). The relationship of these 
putative protective effects with age is less well studied (partly 
due to its rarer frequency), but one suggestion is that ε2 is associ-
ated with more robust neurodevelopment in early life (relative to 
ε3), while another is that it is associated with lower levels of 
neurodegeneration (relative to ε4) in later life (Suri et al., 2013). 
CamCAN’s lifespan cohort allows novel tests for these interac-
tive or additive effects of the ε2 allele with age (green line in 
Figure 1).
The mean effect size of ε4-carrier versus non-carrier status on 
cognition is typically small when averaging across ages. For 
example, the meta-analysis of Wisdom et al. (2011) showed a 
Cohen effect size (d) across studies of d = −0.14 on episodic 
memory and d = −0.05 on global cognition, averaged across ages 
from 20 to 90 years (where d = 0.20 is considered ‘small’). This 
effect size would be difficult to detect with the approximately 
600 participants in the CamCAN imaging sample who have valid 
cognitive, neuroimaging and genetic data, including APOE status 
(see Figure 2); a sample that is considerably smaller than several 
recent large studies (e.g. Lyall et al., 2019a; Marioni et al., 2016; 
Shin et al., 2014). However, if the antagonistic pleiotropy hypoth-
esis is correct, then the effect size depends on age, such that the 
effect size for the interaction between APOE and age could be 
bigger than the effect size averaging over age (see Figure 1 and 
section ‘Methods’). Consistent with this view, the meta-analysis 
of Wisdom et al. (2011) also found a significant linear effect of 
age, with the detrimental effect of ε4 increasing with age. 
Similarly, more recent studies (e.g. Lyall et al., 2019b; Marioni 
et al., 2016; Shin et al., 2014) have generally reported stronger 
Figure 1. Illustration of potential interactions between APOE status 
and age on cognitive and/or brain health.
According to the ‘antagonistic pleiotropy’ hypothesis, ε4-carriers (red line) 
experience a benefit in early life but a detriment in later life, relative to non-
carriers (ε3ε3 group, blue line). The characteristics of ε2-carriers (green line) are 
less clear, but generally thought to benefit later in life. Note that every person 
has two alleles, so ‘ε4-carrier’ (indicated by ‘ε4*’ in legend) means someone with 
ε4ε4 or ε3ε4 (but excluding ε4ε2 – see text for more details).
Figure 2. Classical power analyses for (any) polynomial term of GLM 
for (1) separate, categorical analysis of ε3ε3 versus ε2+ε4− (green 
line), (2) separate, categorical analysis of ε4+ε2− versus ε3ε3 (red 
line) and (3) linear, parametric ‘dose’ effect of ε2−/ε4+ load (blue 
dotted line). The vertical lines and numbers refer to prior effect sizes 
in literature, as described in text.
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detrimental effects of ε4 in older than younger groups. Moreover, 
in a large (genome-wide) study of multiple cohorts, Davies et al. 
(2015) found that rs10119 – a single-nucleotide polymorphism 
(SNP) neighbouring the APOE locus – showed a negative corre-
lation of R = −0.424 between the average cohort age (from 55 to 
80 years) and the effect size for this SNP on general cognitive 
ability. This corresponds to an interaction effect size of d = −0.936 
(Figure 2). Furthermore, the power to detect such an interaction 
between age and APOE status is likely to benefit from the wider 
age range in CamCAN than is typically available in the cohorts 
that have been tested so far (such as the UK Biobank), which 
have tended to focus on middle and older ages. 
In addition to cognition, the APOE variants have been associ-
ated with differences in brain structure and function, as measured 
with magnetic resonance imaging (MRI) or magnetoencephalog-
raphy (MEG). Indeed, it is possible that such allele-specific 
effects might be seen earlier in the lifespan than they can be seen 
in cognition (Siebner et al., 2009). This could be because neuro-
imaging measures are more sensitive than behavioural measures 
at detecting subclinical abnormalities. Another possibility for the 
lower sensitivity of cognitive measures (versus brain measures) is 
that young ε4-carriers show compensatory changes (e.g. increased 
functional activity or connectivity) that maintain cognitive perfor-
mance comparable to non-carriers; however, at some point in 
older age, these compensatory mechanisms fail and a deleterious 
effect on cognition is unmasked. A related idea is that the increased 
activity in younger ε4-carriers ‘may cause neurophysiological 
changes that lead to earlier age-related decline in brain function’ 
(Buckner et al., 2008; Filippini et al., 2009a). Both of these 
hypotheses predict an interaction between APOE variant and age. 
Indeed, if one were to find a greater interaction between APOE 
and age on brain measures than on cognitive measures, this would 
support the idea that brain function compensates for the detrimen-
tal effects of APOE on brain structure, compensating in youth but 
no longer being able to compensate in old age. 
Many neuroimaging studies of APOE variants have focused 
on volumetric differences in structural (e.g. T1-weighted) MRI 
images, particularly atrophy of grey matter in regions of the 
medial temporal lobe, such as the hippocampus, which occurs 
early in AD and is associated with memory problems. 
Unfortunately, the results have been mixed, with most studies 
not finding a mean effect of APOE, ε4 or ε2, particularly in hip-
pocampus (e.g. Bunce et al., 2012; Filippini et al., 2009b; Habes 
et al., 2016; Jack et al., 2015; Lyall et al., 2019b; Machulda 
et al., 2011; Westlye et al., 2011; Taylor et al., 2015; see Table 1 
in Lyall et al., 2013 and Fouquet et al., 2014 for review). 
Nonetheless, despite the converging evidence against any effect 
of APOE, we tested main effects on hippocampal volume and 
the interaction with age because of their historical and theoreti-
cal relevance.
Other MRI studies have examined effects of APOE on white-
matter integrity, for example, the number of white-matter hyper-
intensities (WMHI) in MRI images (e.g. Lyall et al., 2019b). 
While CamCAN does not have MRI data suitable for estimating 
WMHI in the full sample, it does possess diffusion-weighted 
images (DWIs) that can be used to estimate diffusion tensor imag-
ing (DTI) metrics. Given APOE’s established role in cholesterol 
transport, it is conceivable that different alleles may modulate 
age-related myelin degradation, which would affect such DTI 
metrics. Two studies (Heise et al., 2011; Westlye et al., 2012) with 
samples of 73 and 203 adults, respectively, found similar effects 
of ε4- and ε2-carriers (relative to ε3ε3) on various DTI metrics, 
including increases in mean diffusivity (MD) and decreases in 
fractional anisotropy (FA), where both of these changes are reflec-
tive of poorer WM health. Similar MD increases and FA decreases 
have been reported in AD (Stebbins and Murphy, 2009). However, 
the parallel rather than opposite effect of ε4 and ε2, coupled with 
the fact that neither study found any interactions with age, led 
both groups to suggest that the APOE variants reflected neurode-
velopmental differences, rather than any changes related to AD. A 
study of N ~ 650 older individuals (aged ~73 years) found reduced 
FA in ε4-carriers (but not ε2-carriers) in two of 15 major white-
matter tracts, but not in the first principal component across tracts 
(Lyall et al., 2014). A more recent and much larger study from the 
UK Biobank (Lyall et al., 2019b) found neither effect of ε4 nor 
interaction with age, on the first principal component of MD or FA 
across 22 WM tracts. However, as the authors noted, the restricted 
age range of mostly 50–70 years may have limited their ability to 
detect age effects. CamCAN’s larger range of ages make it better 
suited to investigate the effects of ε4 and ε2 and their interactions 
with age.
Several studies have assessed functional connectivity between 
brain regions, acquiring, for example, blood oxygenation level 
dependent (BOLD)-weighted MRI while people rest. There has 
been a focus on the default mode network (DMN), which includes 
hippocampus as well as medial parietal and medial frontal regions. 
Using independent component analysis (ICA), for example, 
Westlye et al. (2011) reported increased expression of DMN con-
nectivity for N = 33 ε4-carriers versus N = 62 non-carriers (aged 
50–80 years). Based on the similarity of the DMN and the regions 
disrupted in AD, it has been suggested that enhanced metabolism 
in the DMN may provide regional conditions that are conducive 
to amyloid deposition (Buckner et al., 2008). However, 
Trachtenberg et al. (2012) found similar effects of ε4 and ε2 on 
functional connectivity in a young group and argued that the 
effects of APOE do not relate only to AD risk, but rather to the 
putative role of APOE in neurodevelopment (see also Deary et al., 
2002; O’Donoghue et al., 2018). Moreover, other results are 
divergent, with both increased and decreased functional connec-
tivity reported for APOE variants (e.g. Damoiseaux et al., 2012; 
Filippini et al., 2009a; Fleisher et al., 2009; Machulda et al., 2011; 
Pietzuch et al., 2019; Sheline et al., 2010 for review). Indeed, 
Pietzuch et al. (2019) suggested that this divergence ‘may relate to 
the age of the sample groups’ (see also Damoiseaux et al., 2012 
for potential moderating effects of age and sex). Indeed, in a 
cross-sectional study, Shu et al. (2016) reported that, while both 
ε2- and ε4-carriers had decreased DMN connectivity compared to 
ε3 homozygotes, they showed opposite effects of age.
Interpretation of changes in functional connectivity measured 
by functional MRI (fMRI) is non-trivial, since the measures can 
be affected by vascular as well as neural factors (Geerligs et al., 
2017; Tsvetanov et al., 2016). MEG provides a more direct meas-
ure of neural activity, albeit with worse spatial resolution than 
fMRI. To our knowledge, Koelewijn et al. (2019) is the only 
MEG study to examine resting-state functional connectivity in 
APOE variants with an appreciable number of N = 159 healthy 
adults (N = 159; 51 ε4-carriers versus 108 non-carriers aged 18–
65 years, though mostly young; see Cuesta et al., 2015, for a 
smaller study). These authors reported that they could classify ε4 
status with an accuracy of 63.5%, based on the strongest 
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connections between brain regions. Though the CamCAN data 
were recorded with eyes closed rather than open and on a differ-
ent MEG system, we replicated their analysis pipelines, as closely 
as possible, for the CamCAN data.
In summary, we tested the antagonistic pleiotropy hypothesis, 
with regard to both ε4- and ε2-carriers, on a number of cognitive 
and brain measures that are available in the CamCAN cohort; 
specifically, those measures that have been linked to APOE status 
in previous studies, empirically and/or theoretically. We used a 
quadratic expansion of age (see section ‘Methods’) to test for 
interactions between APOE status and age. In the case of signifi-
cant non-linear effects (e.g. inverted U-shaped fits as in Figure 
1), we planned to estimate the age of the vertex (peak scores) for 
each allele group. Since it was possible that we would identify no 
significant quadratic component (if, for example, the beneficial 
effects of ε4 or ε2 are only seen below the age of 18 years, that is, 
during early development), such that any interaction between age 
and APOE status could reflect just an accelerated decline in old 
age, we also compared linear slopes.
Methods
Data selection
None of the CamCAN participants had a diagnosis of dementia 
or mild-cognitive impairment at recruitment; all reported them-
selves to be in good cognitive health, and all scored above con-
ventional cut-offs for dementia on the mini-mental state 
examination (MMSE) and Addenbrooke’s cognitive examina-
tion – revised (ACE-R) screening tests (see Shafto et al., 2014). 
This study was conducted in compliance with the Helsinki 
Declaration and was approved by the local ethics committee, 
Cambridgeshire 2 Research Ethics Committee (reference: 10/
H0308/50). The cognitive, MRI and MEG data from CamCAN 
are available on request from https://camcan-archive.mrc-cbu.
cam.ac.uk/dataaccess/. The cognitive data were already scored 
(available on above website) and the MRI data had already been 
preprocessed (see Taylor et al., 2017).
DNA was prepared from saliva samples, which underwent 
genome-wide genotyping using the Illumina Infinium 
‘OmniExpressExome’ SNP-chip. This chip covers >960,000 
SNP markers spread through the genome, capturing a large pro-
portion of common variation. The common SNPs rs7412 and 
rs429358 were used to determine APOE ε2, ε3 and ε4 allelic sta-
tus of the participants. Full raw genotype data were first filtered 
in GenomeStudio according to standard procedures (Guo et al., 
2014). Additional quality control checks were performed in 
PLINK (removal of SNPs for which Hardy Weinberg p < 1 × 10−6, 
missingness > 0.05, minor allele frequency < 0.05; removal of 
individuals with total SNP missingness > 0.05 or where multidi-
mensional scaling indicated non-European origin). After quality 
control, the data set included 675,373 directly genotyped SNPs. 
Genotype data were imputed using the Haplotype Reference 
Consortium version 1.1 panel in the Michigan Imputation Server 
(https://imputationserver.sph.umich.edu). Genotypes of rs7412 
were extracted from the raw genotype data, while genotypes for 
rs429358 were derived by imputation. Prior studies have shown 
that this imputation procedure has high accuracy for determining 
APOE allelic status (Radmanesh et al., 2014). The phenotypic 
and genotypic data were held in separate laboratories (MRC 
CBU in Cambridge and Max Planck Institute for Psycholinguistics 
in Nijmegen, respectively), and the link between them only de-
blinded when the Stage 1 version of this study was accepted and 
restricted to APOE allelic status.
Choice of dependent variables and models
In order to minimise the number of statistical tests, we restricted 
ourselves to six dependent variables – two cognitive and four 
brain measures – which we deemed to have the strongest prior 
evidence for associations with APOE allelic status (e.g. episodic 
memory) or are most theoretically relevant (e.g. hippocampal 
volume). These measures also have prior effect sizes published in 
the literature with which to estimate power (see section ‘Power 
calculation’ below).
For the cognitive data, we focused on two abilities that have 
shown the most consistent associations with APOE status in the 
literature: (1) fluid intelligence and (2) episodic memory (Davies 
et al., 2015; O’Donoghue et al., 2018; Wisdom et al., 2011). For 
the former, we used the Cattell test (first principal component 
across four sub-tests) and for the latter we used the WAIS logical 
memory test of verbal memory (first principal component across 
immediate recall, delayed recall and delayed recognition) – see 
Shafto et al. (2014) for more details.
For grey matter, we focused on (3) hippocampal volume, as 
extracted following application of FreeSurfer 6.0 (https://surfer.
nmr.mgh.harvard.edu/fswiki/DownloadAndInstall) to 1 mm-iso-
tropic T1-weight magnetization prepared rapid gradient echo 
(MPRAGE) scans (see https://camcan-archive.mrc-cbu.cam.
ac.uk/dataaccess/pdfs/CAMCAN700_MR_params.pdf for fur-
ther details of MRI scans). To correct for inter-individual differ-
ences in head size, hippocampal volumes were adjusted for total 
intracranial volume (TIV).
For white matter, we used (4) the participant loadings of the 
first principal component of MD values across major white-matter 
tracts defined by the John Hopkins Atlas (averaged across hemi-
sphere, as in de Mooij et al., 2018), derived from 2-mm-isotropic 
DWI data preprocessed according to Taylor et al. (2017).
For resting-state fMRI (rsfMRI) connectivity, we focused on 
(5) mean connectivity within the DMN, following the optimised 
pre-processing pipeline described in Geerligs et al. (2017).
Finally, for the resting-state MEG (rsMEG) connectivity, we 
followed the procedure of Koelewijn et al. (2019) and examined 
(6) the participant loadings of the first principal component of 
connection strengths in source space. For further details of the 
preprocessing of the imaging measures and minor deviations 
from the Stage 1 report, see Supplemental Table 1.
Statistical models
For all six dependent variables, we modelled the effects of age by 
a second-order polynomial expansion, implemented in a general 
linear model (GLM). A standard quadratic expansion of age is 
given by
y x x= + +β β β0 1 2 2
where y  is the dependent variable (e.g. cognitive score), x  is 
(mean-corrected) age and β0 2−  are the polynomial parameters to 
be estimated. Note that there is an equivalent parabolic form
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y x= + −  β β β0 1 2 2( )
in which β2  is the vertex (age of maximal performance as shown 
in Figure 1), which can be estimated as
β β β2 1 22= − /
All regressors of interest in the GLM were Z-scored. The GLMs 
were fit in the MATLAB function ‘apoe_getdata.m’ and equiva-
lently in the R script ‘apoe_lm_brms.R’, available on https://osf.
io/ehs9n/. Outliers on any of the six phenotypic variables were 
defined by residuals that were 1.5 times the interquartile range, 
after adjusting for polynomial effects of age.
In the ‘categorical’ GLMs, the effects of age were modelled 
separately for three sub-groups (Table 1): ε2-carriers without ε4, 
or henceforth the ‘ε2+ε4−’ group (i.e. ε2ε2, ε2ε3); ε4-carriers 
without ε2, or henceforth the ‘ε4+ε2−’ group (i.e. ε3ε4, ε4ε4) 
and the ‘ε3ε3’ reference group who do not carry either ε2 or ε4 
(we ignored any ε2ε4 cases, which were less than 3% of our sam-
ple, as is common in the field).
Two comparisons of pairs of groups were planned: (1) ε3ε3 
versus ε2+ε4− and (2) ε4+ε2− versus ε3ε3. The mean and linear 
age terms were tested separately as one-tailed t-contrasts, where 
the tail of the test depended on the direction of the expected effect 
on the specific phenotypic variable (e.g. a detrimental effect of ε4 
would produce lower Cattell scores of fluid intelligence, but 
higher values of MD scores of white-matter integrity). For scores 
like Cattell, where larger values mean better performance, one 
would expect a negative difference for both planned comparisons, 
that is, the ε3ε3 group minus the ε2+ε4− group (since ε2 is 
hypothesised to be beneficial) and the ε4+ε2− group minus the 
ε3ε3 group (since ε4 is hypothesised to be detrimental). This 
direction applies to both the mean and the linear slope of the poly-
nomial effect of age (e.g. the slope of the age effect should be 
more negative for the ε3ε3 group than the ε2+ε4− group and for 
the ε2+ε4− group than the ε3ε3 group). The quadratic term was 
predicted, on the basis of the antagonistic pleiotropy hypothesis, 
to be negative for all groups (i.e. an inverted U-shape), but can be 
combined with the mean and linear terms to estimate the vertex 
(inflexion point) of a parabolic fit (Figure 1), as detailed above, 
which was predicted to be earlier for ε4-carriers than non-carriers. 
The above categorical analyses allowed the effects of ε4 and ε2 to 
differ qualitatively.
A second ‘parametric’, or gene-dose, GLM modelled a linear 
effect of a decreasing number of ε2 alleles and increasing num-
bers of ε4 alleles, which is potentially a more sensitive model if 
the two alleles have the same quantitative (and additive) effects. 
The latter is consistent with evidence for a load effect for ε4 at 
least (e.g. Wisdom et al., 2011), including the cumulative 
increased risk for AD (Farrer et al., 1997).
Power calculation
We simulated statistical power for various effect sizes and 
N = 608 participants. The number of 608 was an estimate of the 
number of CamCAN individuals who have valid cognitive and 
genetic data; an estimate made before the genetic and pheno-
typic data were combined (see section ‘Results’ for final num-
bers for each phenotypic variable). To simulate random genetic 
sampling, multiple random draws were simulated from the 
expected population frequencies of each allele combination. 
The ‘apoe_power_simulations.m’ MATLAB script for these 
analyses is provided in the website: https://osf.io/ehs9n/. Using 
a Bonferroni-corrected alpha value of 0.05/6 (given the six out-
come variables above – no correction was made for the three 
contrasts of APOE groups, because these contrasts share sub-
sets of the same data, nor for the number of polynomial effects, 
since the main interest was in non-zero terms that were relevant 
to the antagonistic pleiotropy hypothesis), the cohort provides 
>80% power for effect sizes between 0.20 and 0.44 (i.e. small 
to medium effects), depending on the comparison and model 
(Figure 2; note that although we use ‘power’ to refer to a single 
study, strictly it refers to the expected outcome over a series of 
studies). The following effect sizes from the literature are 
shown in Figure 2:
1. The effect size of d = −0.14 of ε4 on episodic memory 
when averaging across all adult ages (Wisdom et al., 
2011), for which our power is only 17% for ε4-carriers 
versus non-carriers or 41% if there is a parametric effect 
of ε2−/ε4+ load.
2. More important for the present hypothesis about age-
dependence of ε4 effects, the recent meta-analysis of 
Davies et al., 2015 found an effect size of d = −0.936 for 
the linear effect of age for the rs10119 region associated 
with APOE on general cognitive ability, for which the 
present power is close to 100% in all cases.
3. For hippocampal volume, Taylor et al. (2015) reported 
an effect size for ε4 of d = −0.56, for which this study has 
a power of close to 100% (and 95% for ε2 if the effect is 
comparable in size).
4. For MD from DTI, Westlye et al. (2012) reported an MD 
effect size for ε4 of d = +0.77, for which the present 
power is close to 100% in all cases.
5. For rsfMRI, Westlye et al. (2011) reported an effect size 
for ε4 of d = +1.23 in right hippocampus/amygdala (part 
of DMN), for which we have ample power (off the scale 
in Figure 2). Note that, however, the effect sizes for this 
functional connectivity effect and for the DTI effect in 
the above Westlye et al.’s paper may be biased upwards 
because both were selected after thresholding voxels that 
showed a basic effect of APOE status.
6. For rsMEG, Koelewijn et al. (2019) reported an area-
under-curve of the receiver-operating characteristic 
(ROC) of 63.5% for classification of ε4 status. This cor-
responds to a Cohen’s d of +0.49 (Salgado, 2018), for 
which this study has a power of close to 100%.
Bayes factors
For the same tests on the six dependent variables, we also calculated 
the Bayes factors (BFs) for the null versus alternative hypothesis for 
the APOE-by-age interaction terms. For this, we used the Savage–
Dickey ratio, after logspline interpolation of the posterior sampling 
distribution, generated from 100,000 Markov chain Monte Carlo 
(MCMC) iterations of the ‘brm’ function from the ‘brms’ R pack-
age (Bürkner, 2017, 2018) using the same linear model as for the 
above classical statistics. This is provided in the R script ‘apoe_lm_
brms.R’ on https://osf.io/ehs9n/. We imposed unit normal priors on 
all of the (Z-scored) polynomial terms for the age-by-APOE status 
interactions. Note that this is a deviation from Stage 1 of this study, 
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which stated that we would use Jeffreys-Zellner-Siow (JZS) priors. 
This is because the sampling of a Cauchy prior on the mean (with 
scale 1/√2), as required by the JZS approach, produced unstable 
posterior distributions. Nonetheless, simulations show that the BFs 
are very similar for both priors (see https://jaquent.github.io/post/
comparing-different-methods-to-calculate-bayes-factors-for-a-sim-
ple-model/).
Covariates of no interest
Covariates of no interest included: (1) sex (which, though bal-
anced in CamCAN sample, has been shown to modulate APOE 
effects in some studies, e.g. Damoiseaux et al., 2012): (2) educa-
tion level (since this tends to increase with year of birth in cross-
sectional data and is known to correlate with cognitive measures 
later in life), (3) an estimate of socio-economic status (SES) and 
(4) a summary measure of cardiovascular health (first principal 
component of CamCAN’s measures of blood pressure and elec-
trocardiogram (ECG); see Tsvetanov et al., 2015), since this has 
also been shown to be affected by APOE (e.g. Lyall et al., 2016; 
Oberlin et al., 2015). Separate models were fit with versus with-
out covariates because education, cardiovascular health and age 
covary positively and therefore cannot be disentangled with 
cross-sectional data. Note that, while the Stage 1 report stated 
that genetic ancestry would also be a covariate, because it became 
clear after molecular genetic analysis that the majority of the 
sample had European white ancestry, we excluded the small 
number of individuals with a different ancestry from the analyses 
(see start of section ‘Results’), so it was no longer necessary to 
include ancestry as a covariate.
SES was estimated by total family income, ranked into five 
levels (<£18k, <£31k, <£52k, <£100k and >£100k per 
annum) and had 27 missing values. Education was also ranked 
into five levels (no qualifications at age 16, practical qualifica-
tions at age 16, academic qualifications at age 16, qualifications 
at age 18 and university degree or higher), with 47 missing val-
ues. Cardiovascular health was the first principal component of 
mean heart rate and heart rate variability (after low and high-
pass filtering of the ECG recorded during the MEG session), as 
well as systolic and diastolic blood pressure, after excluding 
169 missing values, respectively. All missing values were 
replaced by the predictions of a quadratic fit of age to remaining 
values, and the results Z-scored for each variable.
Results
There were a total of 651 genetic samples with matching pheno-
typic IDs, of which three were excluded for low quality and 
three were excluded because they were related to others in the 
sample. Of the remaining 645, principal component analyses of 
genome-wide SNP data showed that only 35 had non-European 
ancestry, which we also excluded so as to optimise the homoge-
neity of the sample, leaving a total sample of 610 participants. 
The frequency of APOE alleles closely matched that expected 
from the frequency within healthy Europeans (Eisenberg et al., 
2010), as seen in Figure 3. There were 78 in the ε2+ε4− group, 
159 in the ε4+ε2− group and 357 in the ε3ε3 group (plus 16 
ε2ε4 carriers, who were not analysed further, as explained in 
section ‘Methods’).
The numbers of participants with data for each phenotypic 
variable are shown in the leftmost column of Table 1. From these, 
outliers that were 1.5 times the interquartile range, after adjusting 
for linear and quadratic effects of age, were removed, producing 
the final numbers in the rightmost column of Table 1. The white-
matter MD measure contained the highest number of outliers, 
Figure 3. Number of CamCAN participants (out of 610) with each APOE 
genotype (filled bars) and number expected from White Europeans 
(empty bars).
Table 1. Number of outliers and valid data points for each phenotypic variable for each of the three genetic groups: ε2+ε4−, ε3ε3 and ε4+ε2−.
Count N initial N outliers (excluded) N final
Phenotypic variable ε2+ε4− ε3ε3 ε4+ε2− Total ε2+ε4− ε3ε3 ε4+ε2− Total
Fluid intelligence 560 0 2 1 3 74 331 152 557
Episodic memory 592 0 1 1 2 78 355 157 590
Hippocampal volume 546 1 4 7 12 70 322 142 534
White-matter MD 525 7 26 12 45 63 286 131 480
rsfMRI in DMN 548 0 6 3 9 71 322 146 539
rsMEG PCA 514 2 7 7 16 67 295 136 498
MD: mean diffusivity; rsfMRI: resting-state functional magnetic resonance imaging; DMN: default mode network; rsMEG: resting-state magnetoencephalography; PCA: 
principal component analysis.
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most likely because diffusion-weighted MRI data are well-known 
to be sensitive to noise, such as that caused by head motion.
Scatter plots of the six phenotypic variables against age are 
shown in Figure 4. Additional information regarding definition 
of these variables is provided in Supplemental Table 1. All six 
variables showed significant effects of age (see Supplemental 
Table 2). The fits come from a second-order polynomial expan-
sion of age to each APOE group. There was little apparent evi-
dence for antagonistic pleiotropy (i.e. different effects of age for 
each group), though the Cattell test of fluid intelligence showed 
some suggestion of ε4-carriers performing worse in later life and 
better in early life (i.e. for red line relative to blue and green lines 
in top left panel of Figure 4). Although the quadratic component 
was significant for three variables, it was never large relative to 
the linear component, and more importantly, it never differed sig-
nificantly between APOE groups (see the next section), meaning 
that there was little value in comparing the peaks across APOE 
groups (i.e. age of maximum or minimum value).
Planned comparisons using classical 
(frequentist) statistics
Results of the critical interactions between APOE and age are 
shown in Table 2. These come from the same linear model as 
shown in Figure 4 (without any covariates). In the three groups of 
columns, the first two groups refer to the two planned categorical 
contrasts across APOE groups of (1) ε3ε3 versus ε2+ε4−, (2) 
ε4+ε2− versus ε3ε3; the third group of columns refers to (3) the 
parametric contrast of ε2−/ε4+ dose, with a linear increase across 
ε2ε2, ε2ε3/ε3ε2, ε3ε3, ε3ε4/ε4ε3 and ε4ε4. The sign of these 
three contrasts matches the sign of the expected, prior effect size 
for ε4-carriers versus non-carriers reported in section ‘Power cal-
culation’ (i.e. the direction of effect was predicted to be negative 
for first three phenotypic variables and positive for last three phe-
notypic variables). Within each group, the parameter estimates for 
the interactions between APOE status and zeroth-, first- and sec-
ond-order polynomial effects of age are shown (where the zeroth-
order effect is equivalent to the main effect of APOE status).
The models fit the data well for the first four phenotypes 
(explaining 14%–70% of the variance). The fit was not so good 
for fMRI and MEG (explaining only approximately 5% of the 
variance, though still significant), which we attribute to these 
data being noisier. Only one of the three polynomial effects for 
any of the three contrasts for any of the six phenotypic variables 
survived our pre-specified, one-tailed alpha value of 0.05/6. This 
was the zeroth-order effect on resting-state fMRI connectivity in 
the default mode network, where connectivity was higher on 
average for the ε4+ε2− group than ε3ε3 group (cf. red and blue 
lines in middle bottom panel of Figure 4). This is consistent with 
Westlye et al. (2011), but because this main effect of the ε4 allele 
did not interact with either of the linear or quadratic age terms, it 
provides no support for the antagonistic pleiotropy hypothesis.
The only phenotypic variable to show any suggestion of the 
predicted interaction between APOE status and age was the 
Cattell measure of fluid intelligence (surviving p < 0.05 but not 
Figure 4. Scatter plots for each phenotypic variable against age, grouped by APOE status (colour). Outliers are indicated by crosses (but were 
excluded from analyses). The solid lines show second-order polynomial fits of age on remaining points for each APOE group.
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correction for multiple comparisons), for which the slope was 
more negative for the ε4+ε2− group than ε3ε3 group (cf. red and 
blue lines in top left panel of Figure 4), and was negatively 
related to increasing ε2−/ε4+ dose in the parametric model.
The only other effect with p < 0.05 (uncorrected) was the 
zeroth-order effect for the ε4+ε2− group on hippocampal vol-
ume, which tended to be larger on average than in the ε3ε3 group. 
However, we suspect that this is a false positive since it was in 
the opposite direction to our predictions, and so we do not con-
sider it further.
Adjusting for covariates
The above linear model was repeated with five additional covari-
ates: male/female sex, education level, SES and cardiovascular 
health. The inclusion of these covariates did not reveal any new 
significant effects of APOE (Supplemental Table 3). The greater 
DMN fMRI connectivity for the ε4+ε2− group relative to the 
ε3ε3 group continued to survive correction, and the parametric 
effect of dose on the linear age slope for fluid intelligence contin-
ued to survive p < 0.05 uncorrected. The linear interaction 
between age and ε4+ε2− group and ε3ε3 group on fluid intelli-
gence no longer survived p < 0.05 after adjusting for covariates.
In short, there was no evidence for the antagonistic pleiotropy 
hypothesis using classical null-hypothesis testing. Since this 
could reflect false negatives, given our relatively small sample 
for genetic effects, we calculated BFs for the null versus alternate 
hypotheses.
BFs
Since the dominant effect of age on phenotypic variables was 
linear (see Supplemental Table 1), and linear effects were 
reported in the prior literature (see section ‘Power calculation’), 
we only report here the BFs for the first-order polynomial term.
The three columns in Table 3 show, for each APOE analysis: 
(1) BFs for the linear interaction between Age and APOE status 
being zero, given a prior expectation of zero ( ‘Lin = 0’), (2) BFs 
for the linear interaction between age and APOE status being 
greater or less than zero ( ‘Lin > 0’ or ‘Lin < 0’), given a prior of 
greater or less than zero, where the greater/lesser direction depends 
on the analysis (i.e. ε2 being protective would predict a more posi-
tive (less negative) slope than the reference group, and ε4 being a 
risk factor would predict a more negative slope than the reference 
group) and (3) BFs for the linear interaction between age and 
APOE status being zero given the prior expectation of an effect 
size (P) equal to that from the literature that was used to power this 
study ( ‘Lin = P’), as listed in section ‘Power calculation’.
In all cases, the BFs provided ‘substantial’ (BF > 3) or ‘strong’ 
(BF > 10) evidence (https://en.wikipedia.org/wiki/Bayes_factor) 
for no interaction between APOE status and age on any of the 
phenotypic variables, regardless of whether their prior expecta-
tion was equal to zero or equal to the effect size from the litera-
ture, with the exception of fluid intelligence: While there was 
strong evidence for no interaction between the ε2 allele and age 
on fluid intelligence, this was not true for the predicted direction 
of interaction between ε4 allele and age (or of overall ε4 load), 
where the BFs were around 2, that is, ambiguous.
General discussion
This study provided no support for, and mostly evidence against, 
the ‘antagonistic pleiotropy’ hypothesis (Han and Bondi, 2008), 
whereby the ε4 variant of APOE is proposed to be advantageous 
in early life but disadvantageous in later life. The study also pro-
vided evidence against the related hypothesis that the ε2 variant 
of APOE is advantageous, particularly in later life (Suri et al., 
2013). While our sample was relatively small for genetic analysis 
of cognitive and neural phenotypes, it was sufficiently powered 
for classical statistics when based on previous effect sizes 
reported, and moreover, furnished BFs that provided evidence in 
favour of the null hypothesis that these APOE variants do not 
interact (linearly) with age in their putative effects on brain struc-
ture or cognition.
The only effect of APOE status that survived our a priori cor-
rection for the six phenotypic variables tested was the main effect 
Table 3. Bayes factors (BFs) for various hypotheses about the first-order (linear) effect of age being zero (BF01) for each contrast and each 
phenotypic variable, given various means for a unit normal prior.
Contrast ε3ε3 group versus ε2+ε4− group ε4+ε2− group versus ε3ε3 group Parametric (dose) effect of ε2−/ε4+
BF01 Lin = 0 Lin < 0 Lin = P Lin = 0 Lin < 0 Lin = P Lin = 0 Lin < 0 Lin = P
Fluid intelligence 18.63 29.79 29.42 4.08 2.09 5.99 2.30 1.16 3.31
Episodic memory 15.69 23.30 15.82 13.56 8.05 13.72 13.56 8.05 13.72
Hippocampal volume 19.40 17.71 22.65 25.11 20.95 29.20 19.43 11.79 22.15
BF01 Lin = 0 Lin > 0 Lin = P Lin = 0 Lin > 0 Lin = P Lin = 0 Lin > 0 Lin = P
MD of WM tracts 22.21 15.35 29.31 22.17 63.92 30.52 24.36 14.58 32.18
DMN rsfMRI connectivity 9.10 29.84 21.08 20.66 21.45 43.90 18.91 27.59 41.65
rsMEG connectivity 10.59 6.62 11.65 15.13 32.11 17.38 22.26 25.64 25.28
BF: Bayes factor; MD: mean diffusivity; WM: white matter; DMN: default mode network; rsfMRI: resting state functional magnetic resonance imaging; rsMEG: resting state 
magnetoencephalography.
The column headings for each analysis are explained in the text. The value of P in the column ‘Lin = P’ was determined from the literature cited in section ‘Power 
calculation’, that is, P = [−0.936, −0.14, −0.56, +0.77, +1.23, +0.49] for the six phenotypic variables. The direction of the one-tailed test in the column (i.e. ‘Lin > 0’ or 
‘Lin < 0’) was determined by the sign of P (i.e. negative for the first three phenotypic variables and positive for the remaining three).
10 Brain and Neuroscience Advances
of ε4-carriers (more precisely, our ε4+ε2− group versus our ε3ε3 
reference group) on the mean fMRI functional connectivity 
within the default mode network. This reflected higher connec-
tivity for the ε4-carriers, consistent with Westlye et al. (2012). 
More importantly, there was no evidence that this effect inter-
acted with age, and therefore even if it reflects a true genetic 
effect on brain functional connectivity, it is not evidence for the 
antagonistic pleiotropy hypothesis.
While all phenotypic variables showed strong associations 
with age, there was only one suggestion that such age associa-
tions depended on APOE status, namely, a steeper, linear age-
related decline in fluid intelligence in the ε4+ε2− group than 
ε3ε3 group. This effect did not survive correction for multiple 
comparisons. Moreover, the BF for this linear effect was ambigu-
ous, so this effect needs replication before providing support for 
the antagonistic pleiotropy hypothesis.
None of the analyses showed any evidence of differences for 
ε2-carriers (i.e. when comparing our ε4+ε2− group versus our 
ε3ε3 reference group). While the number of ε2-carriers was 
lower than ε4-carriers, the lack of interaction between ε2 and age 
is unlikely to simply reflect low power, because BFs provided 
evidence (BFs > 9) for the interaction being zero.
The classical power estimates may have been over-estimated 
because the effect sizes reported in the literature are likely to be 
inflated owing to publication bias and/or ‘winner’s curse’. 
Indeed, the BFs for the null hypothesis were highest when the 
prior mean was based on a published effect size. Nonetheless, the 
BF still provided substantial to strong evidence for no effect even 
when the prior mean was zero.
While this study had lower power than many previous stud-
ies of APOE on cognition, it is nonetheless larger than many 
prior APOE studies using neuroimaging measures, particularly 
measures of functional connectivity using fMRI or MEG, which 
often use small and/or biased samples of the population. Relative 
to these studies, this study gains power by virtue of the wide and 
near-uniform age range from 18 to 88 years, in a population-
derived sample. Nevertheless, it is important to note that, by 
only considering adults, we cannot address a version of the 
antagonistic pleiotropy hypothesis in which the interactions 
between APOE status and age only occur during cognitive and 
brain development, that is, in individuals under 18 years. This 
issue could be examined in larger cognitive and neuroimaging 
lifespan cohorts like the European LifeBrain consortium 
(Walhovd et al., 2018).
Finally, there are other caveats associated with our study. First, 
there may be other types of bias in the selection of adults used in 
this study, particularly those towards the older end of our age range, 
for example, owing to survival bias and exclusion of those with 
evidence of cognitive decline. Indeed, it is possible that the effects 
of APOE variants are only detectable in individuals with AD pathol-
ogy (e.g. Vemuri et al., 2010) and there were few such people in our 
cohort, even those in the pre-symptomatic phase of AD. There will 
also be a bias induced by the exclusion of those who were unable to 
undergo an MRI scan, for example, because of cardiovascular prob-
lems that require a pacemaker or stent, but which might also be 
related to APOE allelic status and cognitive/brain health. Second, 
our sample only included White Europeans (Caucasians), whereas 
APOE variants may have stronger effects in other genetic groups, 
and we did not have any direct measures of neuropathology or take 
into account potential effects of a range of medications. Third, this 
is a cross-sectional sample, which may be confounded with effects 
of birth-year and is unable to examine true ageing within individu-
als. Fourth, we cannot discount a role for antagonistic pleiotropy for 
phenotypic measures that we did not examine in this study such as 
other measures of cognition or the brain.
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